Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 29, 2026, 11:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–46 of 46 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Cetirizine Clear all

Conditions: Allergic Rhinitis
Interventions: Cetirizine, Placebo; Drug · Other
Lead sponsor: Queen's University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Neuromyelitis Optica
Interventions: cetirizine; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 85 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Allergic Conjunctivitis
Interventions: AC-170 0.24%, AC-170 0%; Drug
Lead sponsor: Aciex Therapeutics, Inc.; Industry
Eligibility: 10 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Healthy
Interventions: Claritin; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 65 Years
Enrollment: 340 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Allergic Conjunctivitis
Interventions: AC-150 Combo, AC-150A 0.1%, AC-150B 0.005%, Vehicle; Drug
Lead sponsor: Aciex Therapeutics, Inc.; Industry
Eligibility: 10 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Healthy
Interventions: Cetirizine Hydrochloride 10 mg tablets, single dose, Zyrtec® 10 mg tablets, single dose; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Morrisville, North Carolina

Conditions: HER2-negative Breast Cancer, Metastatic Breast Cancer, Metaplastic Breast Carcinoma, TNBC - Triple-Negative Breast Cancer
Interventions: L-NMMA; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 3
States / cities: Bethesda, Maryland • Houston, Texas

Conditions: Atopic Disease (Including Allergic Conjunctivitis)
Interventions: Drug: AC-170 0.24%, AC-170 0%; Drug
Lead sponsor: Aciex Therapeutics, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 512 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Seasonal Allergic Rhinitis
Interventions: fexofenadine HCl; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Actinic Keratoses
Interventions: Antihistamine Cetirizine Hydrochloride, Placebo; Drug · Other
Lead sponsor: Goldman, Butterwick, Fitzpatrick and Groff; Other
Eligibility: 19 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: San Diego, California

Conditions: Allergic Rhinitis
Interventions: Cetirizine, Levocetirizine, Placebo; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 77 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Allergic Conjunctivitis
Interventions: AC-170 0.24%, AC-170 0%; Drug
Lead sponsor: Aciex Therapeutics, Inc.; Industry
Eligibility: 10 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Healthy
Interventions: Cetirizine Hydrochloride 10 mg tablet; Drug
Lead sponsor: Ranbaxy Laboratories Limited; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: Cetirizine HCl Tablets 10 mg, Zyrtec® Tablets 10 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy Subjects
Interventions: AC-170 0.24%, AC-170 Vehicle; Drug
Lead sponsor: Nicox Ophthalmics, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 516 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Allergic Conjunctivitis
Interventions: AC-170 0.05%, AC-170 0.1%, AC-170 0.24%, AC-170 0%; Drug
Lead sponsor: Aciex Therapeutics, Inc.; Industry
Eligibility: 10 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Migraine
Interventions: PF-05180999, Placebo, 120 mg MR PF-05180999, 360 mg MR PF-05180999, 10 mg cetirizine; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Allergic Rhinitis, Asthma
Interventions: Cetirizine Hydrochloride 1 MG/ML, Placebo - Concentrate; Drug
Lead sponsor: New York City Health and Hospitals Corporation; Other
Eligibility: 6 Years to 20 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Acute Urticaria
Interventions: Test Drug (JDP-205), Active Control (Diphenhydramine); Drug
Lead sponsor: JDP Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 262 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 3
States / cities: Cincinnati, Ohio • Philadelphia, Pennsylvania • Dallas, Texas

Conditions: Irritable Bowel Syndrome, Dermatographism, Post-prandial Diarrhea
Interventions: Antihistamine, Placebo; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Healthy
Interventions: Cetirizine Hydrochloride 10 mg tablets, single dose, Zyrtec® 10 mg tablets, single dose; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Morrisville, North Carolina

Conditions: Healthy
Interventions: Cetirizine Hydrochloride 10 mg tablet; Drug
Lead sponsor: Ranbaxy Laboratories Limited; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Comparability and Standardization of Controlled Allergen Challenge Facilities

Neuromyelitis Optica (NMO) & Cetirizine

A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle

The Efficacy of Claritin in Healthy Subjects

Efficacy of AC-150 for the Treatment of Allergic Conjunctivitis in the Enviro-CAC™ Model

A Relative Bioavailability Study of Cetirizine HCl 10 mg Tablets Under Non-fasting Conditions

Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)

A Multi-Center Study Evaluating the Safety of AC-170 0.24%

Single Center, Randomized, Double-Blind,Crossover Study Comparing Effects Of Single-Dose Fexofenadine HCl 180 mg, Cetirizine 10 mg, and Placebo on Cognitive Performance in Naval Flight Personnel

A Clinical Trial Evaluating the Role of Systemic Antihistamine Therapy in the Reduction of Adverse Effects Associated With Topical 5-aminolevulinic Acid Photodynamic Therapy

Is Levocetirizine Less Sedating Than Cetirizine?

A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle

Bioequivalence Study of Cetirizine Hydrochloride 10mg Tablets Under Fed Conditions

Fasting Study of Cetirizine HCl Tablets 10 mg and Zyrtec® Tablets 10 mg

A Multi-Center, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 Ophthalmic Solution

Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model

A Study of the Safety, Tolerability, Pharmacokinetics, And Effects On Histamine-Induced Wheal Of PF-05180999 In Healthy Adults

The Effect of Cetirizine on Bronchoconstriction

Clinical Trial Comparing JDP-205 to Diphenhydramine Injection for the Treatment of Acute Urticaria

Antihistamines in the Treatment of Irritable Bowel Syndrome With Diarrhea

A Relative Bioavailability Study of Cetirizine HCl 10 mg Tablets Under Fasting Conditions

Bioequivalence Study of Cetirizine Hydrochloride 10mg Tablets Under Fasting Conditions